Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageAbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
In the company’s own words · 10-K filed Feb 20, 2026 · SEC EDGAR
Business segments
Q2 2026 · $13.30BThe company’s own SEC segment disclosure.
- SKYRIZI$4.77B36%
- RINVOQ$1.76B13%
- Other Products$1.11B8%
- Vraylar$1.07B8%
- Botox Therapeutic$864.0M6%
- HUMIRA$425.0M3%
- Other (15)$3.30B25%
AbbVie (ABBV) reported revenue of $17.0B in Q2 2026 (quarter ended June 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 75% and net income of $3.61B (21% of revenue). For the full year FY2025, revenue was $61.2B (+8.6% year on year) and net income $4.23B. Its largest product in 2026-Q2 was SKYRIZI at $4.77B, 36% of the disclosed total, just ahead of RINVOQ at 13%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - General
Ranks #15 of 16 by Smart Score